Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation investigates what sort of impact the Workshop will have in the imminent future and the factors that will determine its success.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation explores qualities which set the event apart from others and expands on its interactive emphasis.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation introduces themes and sessions from Day 2 in Barcelona, including a debate on diet: can vegetarianism cure NAFLD?
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation continues to introduce themes and sessions from Day 1 in Barcelona on May 26. The group dives in-dept to the linkage between Fatty Liver and cancers, and the importance of early liver health screening for cancer prevention.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation highlights feedback from last year’s inaugural event and introduces sessions from this year’s opening in Barcelona on May 26.
From the Vault: What unique challenges arise when building a disease model for NASH prevalence and what strategies do leading modelers use to overcome them?
In this final conversation the Surfers explore the impact they believe ICER’s draft report on resmetirom and obeticholic acid for NASH will have for different stakeholders. The panelists each touch on different perspectives to offer a well-rounded wrap-up.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the group explores the pros and cons of biopsy while critiquing the report’s position on the practice. Discussion goes on to consider challenges for payers trying to determine the economic impacts of these drugs.
The Surfers provide an analysis of a recent draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, Hannah Mamuszka, founder and CEO of Alva10, discusses the report’s assessment of disease prevalence and outlines payer perspectives on prospective drug efficacy.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute, Veronica Miller of the Liver Forum and new guest, Hannah Mamuszka, who is founder and CEO of Alva10. This leading conversation provides an introduction to a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
